Načítá se...
Dimethyl fumarate for relapsing MS
Dimethyl fumarate (DMF) is the latest oral therapy approved for relapsing-remitting multiple sclerosis (RRMS). In 2 placebo-controlled phase III trials, twice daily DMF demonstrated a 44%–53% reduction in annualized relapse rate and 71%–90% reduction in new MRI lesions. In one trial, DMF slowed the...
Uloženo v:
| Vydáno v: | Neurol Clin Pract |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Academy of Neurology
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5798515/ https://ncbi.nlm.nih.gov/pubmed/29473631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0b013e318296f10f |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|